Tandutinib

DB05465InvestigationalSmall molecule

MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several... Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth.

Mechanism: MLN518 inhibits tyrosine kinases; Specifically, it is selective for FLT3, KIT, and platelet-derived growth-factor receptor (PDGFR).
Curator reviewed
Primary indication: Investigated for use/treatment in leukemia (myeloid).Curator reviewed
Formula / weight: C₃₁H₄₂N₆O₄ · 562.703 g/mol (avg)
Code names: CT-53518 · MLN-518

Resolves to

Compound

UNIIE1IO3ICJ9ACAS387867-13-2ChEMBLCHEMBL124660ChEBI90237PubChem3038522

Structure

InChIKeyUXXQOJXBIDBUAC-UHFFFAOYSA-NSMILESCOC1=C(OCCCN2CCCCC2)C=C2N=CN=C(N3CCN(CC3)C(=O)NC3=CC=C(OC(C)C)C=C3)C2=C1

Targets

P36888FLT3P09619PDGFRBP10721KITQ9GZP0PDGFD

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

414Drug interactionsStructured to mechanism, not free text

8Clinical trialsPhase, status and sponsor resolved per trial

20+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tandutinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account